DTNBP1 基因（Dysbindin 基因）与重度抑郁症（MDD）患者：与临床表型无关。

Dysbindin gene (DTNBP1) in major depressive disorder (MDD) patients: lack of association with clinical phenotypes.

机构信息

Fonds de la Recherche Scientifique (FNRS), Laboratoire de Neurologie Expérimentale, Université Libre de Bruxelles, Belgium.

出版信息

World J Biol Psychiatry. 2010 Dec;11(8):985-90. doi: 10.3109/15622975.2010.512089. Epub 2010 Sep 7.

DOI:10.3109/15622975.2010.512089

PMID:20822372

Abstract

OBJECTIVES

Dystrobrevin binding protein 1 (Dysbindin) is a plausible candidate gene for major depressive disorders (MDD) due to its involvement in synaptic signaling, plasticity and localization in the brain.

METHODS

Two intronic SNPs of DTNBP1; rs760761 (P1320) and rs2619522 (P1763) were analyzed in 206 patients with DSM-IV MDD to investigate the functional impact of genotypes on susceptibility for depression and some clinical phenotypes. The Sequenom iPLEX assay (Sequenom, Cambridge, MA) was used for genotyping.

RESULTS AND CONCLUSIONS

Despite the limited power of analysis, our results showed that these two SNPs in DTNPB1 gene were not related to clinical phenotypes such as melancholia, age at onset, suicidality and co-morbid anxiety disorders, as well as to treatment response phenotypes.

摘要

目的

由于与突触信号传递、可塑性以及大脑中的定位有关，肌萎缩侧索硬化症结合蛋白 1（Dysbindin）是重性抑郁障碍（MDD）的一个合理候选基因。

方法

对 206 例 DSM-IV 重性抑郁障碍患者的 DTNBP1 两个内含子单核苷酸多态性(rs760761 [P1320] 和 rs2619522 [P1763])进行分析，以研究基因型对抑郁易感性和某些临床表型的功能影响。采用 Sequenom iPLEX assay（Sequenom，马萨诸塞州剑桥）进行基因分型。